CD86 and neoplasm: Moreover, addition of Akt inhibitor to RT + αPD-L1/αCTLA-4 therapy further enhanced the anti-tumor efficacy by increasing proportion of M1/M2 ratio and CD86+ DCs in a syngeneic murine TNBC model.